Hanall Biopharma Co., Ltd. (009420) Stock Price & Analysis

009420 Stock Chart & Stats

₩37,500.00-₩300.00(-0.79%)

At close: Oct 30 3:30 PM GMT+9

Day’s Range: KRW 36,400.00 - KRW 38,350.00
52-Week Range: KRW 35,900.00 - KRW 73,000.00
Previous Close: KRW 37,800.00
Volume: N/A
Average Volume (3M): 178.67K
Market Cap: KRW 1.90T
Enterprise Value: KRW 3.19T
Total Cash (Recent Filing): KRW 30.20B
Total Debt (Recent Filing): KRW 44.99B
Price to Earnings (P/E): ―
Beta: 0.45
Next Earnings: Jan 20, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue expansion of roughly 2.3x since 2021 indicates meaningful commercial progress and broader business scale. If the company can convert this established top-line growth into sustainable profitability, its larger revenue base could support stronger operating leverage and future investment.

Gross Margin Resilience

Gross margins in the 51–56% range show that the underlying products retain substantial economic value before operating costs. This provides a durable foundation for recovery if management improves the cost structure, controls expenses, and converts gross profit into positive operating earnings.

Moderate Leverage

Although leverage has increased, debt remains moderate relative to equity and the company retains a sizable equity base. This balance-sheet support can provide greater resilience during development or commercialization efforts and leaves more flexibility than a highly leveraged capital structure.

Bears Say

Persistent Losses

The shift from profits to losses across 2024–2025, alongside a TTM net margin near -15%, signals that revenue growth is not currently translating into earnings. Continued losses can weaken retained capital, limit self-funded investment, and increase dependence on operational improvement.

Negative Cash Generation

Recent operating and free cash outflows indicate that the business is consuming rather than producing cash at a time when profitability is already weak. Persistent cash burn can constrain research, commercialization, and other strategic spending unless cash generation improves materially.

Rising Leverage And Negative Returns

The rise in leverage from previously very low levels, combined with negative returns on equity, increases execution risk if losses persist. More debt may add financial obligations while the capital base is producing negative returns, reducing flexibility to absorb further operating weakness.

009420 FAQ

What was Hanall Biopharma Co., Ltd.’s price range in the past 12 months?

Hanall Biopharma Co., Ltd. lowest stock price was ₩35900.00 and its highest was ₩73000.00 in the past 12 months.

What is Hanall Biopharma Co., Ltd.’s market cap?

Hanall Biopharma Co., Ltd.’s market cap is ₩1.90T.

When is Hanall Biopharma Co., Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Hanall Biopharma Co., Ltd.’s earnings last quarter?

Hanall Biopharma Co., Ltd. released its earnings results on Oct 28, 2026. The company reported ₩58.613 earnings per share for the quarter.

Is Hanall Biopharma Co., Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Hanall Biopharma Co., Ltd. pay dividends?

Hanall Biopharma Co., Ltd. does not currently pay dividends.

What is Hanall Biopharma Co., Ltd.’s EPS estimate?

Hanall Biopharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Hanall Biopharma Co., Ltd. have?

Hanall Biopharma Co., Ltd. has 52,240,640 shares outstanding.

What happened to Hanall Biopharma Co., Ltd.’s price movement after its last earnings report?

Hanall Biopharma Co., Ltd. reported an EPS of ₩58.613 in its last earnings report. Following the earnings report the stock price went up 0.654%.

Which hedge fund is a major shareholder of Hanall Biopharma Co., Ltd.?

Currently, no hedge funds are holding shares in KR:009420

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description